


## DAFTAR PUSTAKA

1. Society AC. Colorectal Cancer Facts & Figures 2014-2016. *Colon Cancer Facts Fig* 2014; 1–32.
2. Ferlay J, Soerjomataram I, Dikshit R, et al. *Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer* 2015; 136: E359–E386.
3. Siegel RL, Miller KD, Jemal A. *Cancer statistics, 2016. 2016; 66: 7–30.*
4. Sean M. Ronnekleiv-Kelly, Richard A. Burkhart, Timothy M. Pawlik. *Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. Surg Oncol.* 2016 September ; 25(3): 190–199
5. Info Datin. Data Riset Kesehatan RI 2013
6. NCCN Guideline. *Colon Cancer. NCCN; 2.2018.*
7. NCCN Guideline. *Rectal Cancer. NCCN; 1.2018.*
8. Bond JH. *Polyp guideline: diagnosis, treatment, and surveillance for patients with nonfamilial colorectal polyps. The Practice Parameters Committee of the American College of Gastroenterology. Ann Intern Med* 1993; 119: 836–843.
9. Van Cutsem E, Kohne C, Hitre. *Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med* 2009; 360: 1408–17.
10. T. Yokota. *Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 163-171*
11. Kerr DJ, Young AM, Hobbs FDR. *ABC of Colorectal Cancer. 2001*
12. Devita VT, Hellman S, Rosenberg SA.. *Cancer Principles & Practice of Oncology 10th ed. Lippincott Williams & Wilkins. USA. 2015.*



13. Antonia, et all. *Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology*. J Clin Oncol 35:1453-1486, 2017
14. M. J. Sorich et all. *Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials*. Annals of Oncology 26: 13–21, 2015
15. Kim SE, Paik HY, Yoon H, Lee JE, Kim N, Sung MK. Sex and gender-specific disparities in colorectal cancer risk. *World J Gastroenterol* 2015; 21(17): 5167-5175
16. Marzouk O and Schofield J. Review of Histopathological and Molecular Prognostic Features in Colorectal Cancer. *Cancers* 2011, 3, 2767-2810
17. Skandalakis et all. *Skandalakis Surgical Anatomy : The Embryologic and Anatomic Basis of Modern Surgery*. Chapter 18. Large Intestine and Anorectum. Mc Graw Hill. 2004
18. Brunicardi et all. *Schwartz's Principle of Surgery*. 10<sup>th</sup> Ed. Chapter 29. Colon, Rectum and Anus. Mc Graw Hill. 2015
19. Townsend CM, Beauchamp RD, Evers BM, Mattox KL. *Sabiston Textbook of Surgery : The biological Basis of Modern Surgical Practice*. 19<sup>th</sup> Ed. Chapter 52. Colon and Rectum. Elsevier and Saunders. 2012
20. Syamsuhidayat.R et al : *Panduan Pengelolaan Adenokarsinoma Kolorektal*. Revisi 2006
21. Tannaz A et all. Genetic Alterations in Colorectal Cancer. *Gastrointestinal Cancer Research* 5:19-27. 2012
22. Debas HT. *Gastrointestinal Surgery Pathophysiology and Management*. Chapter 8. Small and Large Intestine. Springer. 2004



23. Panduan Penatalaksanaan Kanker Kolorektal. Komite Penanggulangan Kanker Nasional. Kementerian Kesehatan Republik Indonesia. 2015.
24. Edge S, Byrd D, Compton C, et al. (eds). *AJCC cancer staging manual*. 7th ed. Springer, 2010.
25. Zinner MJ, Ashley SW. Maingot's Abdominal Operation. 12<sup>nd</sup> Ed. Chapter 23 Tumor of The Colon. Chapter 25 Cancer of The Rectum. Lippincott William & Wilkins.
26. Kopetz S, Hoff P, Morris JS, et al. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. *J Clin Oncol* (2010) 28:453-459
27. Strickler J, Hurwitz H. Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. *Oncologist* 2012;17: 513–24.
28. Grothey A, Van Cutsem E, Sobrero A. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013; 381: 303–12.
29. Lièvre A, Bachet J-B, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. *J Clin Oncol* 26(3):374–379, 2008
30. Tejpar S et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer. *JAMA Oncol*. 2017;(2):194-201
31. Stintzing S, Dominik PM, Lisa R, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised double-blind phase 3 trial. *Lancet Oncol* 2016. 1470-2045(16)30269-8.

32. Lieu CH, Renfro LA, de Gramont A. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. *J Clin Oncol.* 2014 Sep 20;32(27):2975-84
33. Majek O, Gondos A, Jansen L, Emrich K, Holleczeck B, et al. (2013) Sex Differences in Colorectal Cancer Survival: Population-Based Analysis of 164,996 Colorectal Cancer Patients in Germany. *PLoS ONE* 8(7): e68077.
34. Missiaglia et al. Distal and Proximal Colon Cancers Differ in Terms of Molecular, Pathological, and Clinical Features. *Ann Oncol.*2014 25(10);1995-2001
35. Arnold D et al. Prognostic and Predictive Value of Primery Tumour Side in Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated Chemotherapy and EGFR direct antibodies in six randomized trials. *Ann Oncol.*2017 28(8):1713-1729
36. World Health Organization (WHO) classification of colorectal carcinoma. *PathologyOutlines.com*.website.<http://www.pathologyoutlines.com/topic/colontumorwhoclassification.html>. Accessed May 25th, 2018
37. Sudigdo S, Sofyan I. *Dasar-Dasar Metodologi Penelitian Klinis Edisi Ke-5* . Sagung Seto. 2014
38. Roni R.. Analisis Ketahanan Hidup 5 Tahun Penderita Karsinoma Kolorektal Di RS Dr. M. Djamil Padang tahun 2003 – 2007. Dibacakan di Muktamar Ahli Bedah Indonesia. 2008.
39. Ahmad S. Hubungan Pola Hidup Dengan *3 Years Survival Rate* Penderita Karsinoma Kolorektal Di Rsup. Dr. M. Djamil Padang Tahun 2010 - 2013. Dibacakan di Muktamar Ahli Bedah Indonesia. 2014
40. Shen Y, Wang J, Han X, Yang H, Wang S, et al. Effectors of Epidermal Growth Factor Receptor Pathway: The Genetic Profiling of KRAS, BRAF, PIK3CA, NRAS Mutations



- in Colorectal Cancer Characteristics and Personalized Medicine. PLoS ONE 8(12): e81628. 2013
41. Hendifar et al. Sex, Age, Ethnicity are Associated with Survival in Metastatic Colorectal Cancer. *Journal of Clinical Oncology*. 2008 26(15):4015-4015
  42. Olwin Nainggolan, Anna Maria S, Marice S. Faktor-faktor Berhubungan dengan Tumor/Kanker Saluran Cerna Berdasarkan Survei Kesehatan Nasional. Puslitbang Biomedis dan Farmasi Departemen Kesehatan RI. 2007
  43. Hamdi M, ZAhari A, Aswiyanti. Profil Karsinoma Kolorektal di Laboratorium PAatologi Anatomi Fakultas Kedokteran Universitas Andalas Periode JANuari 2009 sampai Desember 2011. *Jurnal Kedokteran Andalas*. 2015;4(2): 398-403.
  44. Christie H. Profil Histopatologi Kanker Kolorektal di Instalasi Patologi Anatomik RSUP DR. Sardjito Yogyakarta Tahun 2013. Electronic Thesis & Dissertation (ETD) Gadjah Mada University. Diakses 2 September 2018.
  45. Chiara C, Massimo M, Federica M, et al. Differential Histopathologic Parameters in Colorectal Cancer Liver Metastases Resected After Triplets Plus Bevacizumab or Cetuximab : A Pooled Analysis of Five Prospective Trials. *British Journal of Cancer*. 2018(3): 955-965.
  46. Sally Garneski, Devin Rose. Patient with Right-Sided Colon Cancer Have Poorer Survival Rates than Those with Left-Sided Disease. Presented at American College of Surgeon 2018 Quality and Savety Conference. Orlando. 2018
  47. Petrelli F, et al. Prognostik Survival Associated with Left-Sided vs. Right-Sided Colon Cancer. A Systematic Review and Meta-Analysis. *JAMA Oncol*; 3(2):211-19.